Biotech News

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Aprea Therapeutics (APRE)Aprea Therapeutics2026-06-25 13:46 ESTClinical readout

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to

Open original release

Related news

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

APREAprea Therapeutics2026-06-25 13:46 EST

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

View all latest news

Aprea Therapeutics

Aprea Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

APREAprea Therapeutics2026-06-26 09:25 EST

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States